ERβ splice variant expression in four large cohorts of human breast cancer patient tumors

Breast Cancer Research and Treatment

Volumn 146, Issue 3, 2014, Pages 657-667

  Wimberly, Hallie ^a   Han, Gang ^b   Pinnaduwage, Dushanthi ^c,f   Murphy, Leigh C ^d   Yang, Xiaohong Rose ^e   Andrulis, Irene L ^c   Sherman, Mark ^e   Figueroa, Jonine ^e   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e NATIONAL CANCER INSTITUTE   (United States)

^f MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Antibody validation; Breast cancer prognosis and prediction; Estrogen receptors; Quantitative immunofluorescence; Triple negative breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA 1; ESTROGEN RECEPTOR BETA 1 ANTIBODY; ESTROGEN RECEPTOR BETA 2; ESTROGEN RECEPTOR BETA 5; ESTROGEN RECEPTOR BETA 5 ANTIBODY; PROTEIN ANTIBODY; PROTEIN VARIANT; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA; ISOPROTEIN;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE IMMUNOFLUORESCENCE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VALIDATION PROCESS; AGED; ALTERNATIVE RNA SPLICING; BIOSYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ALTERNATIVE SPLICING; COHORT STUDIES; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MIDDLE AGED; PROGNOSIS; PROTEIN ISOFORMS; RNA, SMALL INTERFERING; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84907597187     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3050-3     Document Type: Article

References (31)

1. Kuiper G, Enmark E, PeltoHuikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93(12):5925-5930. doi:10.1073/pnas.93.12.5925 (Pubitemid 26190778)
2. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price RH, Pestell RG, Kushner PJ (2002) Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277(27):24353-24360. doi:10.1074/jbc.M201829200 (Pubitemid 34951956)
3. Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S, Spelsberg TC (2005) Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol 19(6):1555-1568. doi:10.1210/me.2004-0381 (Pubitemid 41002985)
4. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M (1998) The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 243(1):122-126. doi:10.1006/bbrc.1997.7893 (Pubitemid 28414201)
5. Williams C, Edvardsson K, Lewandowski SA, Strom A, Gustafsson JA (2008) A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27(7):1019-1032. doi:10.1038/sj.onc.1210712 (Pubitemid 351225390)
6. Charn TH, Liu ETB, Chang EC, Lee YK, Katzenellenbogen JA, Katzenellenbogen BS (2010) Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. Mol Endocrinol 24(1):47-59. doi:10.1210/me.2009-0252
7. Poola I, Abraham J, Baldwin K, Saunders A, Bhatnagar R (2005) Estrogen receptors beta4 and Beta5 are full length functionally distinct ER beta isoforms - cloning from human ovary and functional characterization. Endocrine 27(3):227-238. doi:10.1385/endo:27:3:227 (Pubitemid 41456738)
8. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M (1998) Molecular cloning and characterization of human estrogen receptor beta cx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26(15):3505-3512. doi:10.1093/nar/26.15.3505 (Pubitemid 28347221)
9. Leung YK, Mak P, Hassan S, Ho SM (2006) Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA 103(35):13162-13167. doi:10.1073/pnas.0605676103 (Pubitemid 44338933)
10. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S (2003) Estrogen receptor (ER) beta 1 and ER beta cx/beta 2 inhibit ER alpha function differently in breast cancer cell line MCF7. Oncogene 22(32):5011-5020. doi:10.1038/sj.onc.1206787 (Pubitemid 37028337)
11. Peng B, Lu B, Leygue E, Murphy LC (2003) Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol 30(1):13-29. doi:10.1677/jme.0.0300013 (Pubitemid 36305253)
12. (EBCTCG) EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0
13. Clarke M, Collins R, Davies C, Godwin J, Gray R, Peto R, Early Breast Cancer Trialists Collaborative G (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451-1467 (Pubitemid 28227036)
14. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R, (EBCTCG) EBCTCG, (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771-784. doi:10.1016/S0140-6736(11)60993-8
15. Haldosén LA, Zhao C, Dahlman-Wright K (2014) Estrogen receptor beta in breast cancer. Mol Cell Endocrinol 382(1):665-672. doi:10.1016/j.mce. 2013.08.005
16. Murphy LC, Peng B, Lewis A, Davie JR, Leygue E, Kemp A, Ung K, Vendetti M, Shiu R (2005) Inducible upregulation of oestrogen receptor-beta 1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 34(2):553-566. doi:10.1677/jme.1.01688 (Pubitemid 40585201)
17. Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8(11):1323-1327. doi:10.1038/nm791 (Pubitemid 35373567)
18. Moeder CB, Giltnane JM, Moulis SP, Rimm DL (2009) Quantitative, fluorescence-based in situ assessment of protein expression. Methods Mol Biol 520:163-175. doi:10.1007/978-1-60327-811-9-12
19. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D, Toronto Breast Cancer Study Group (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16(4):1340-1349 (Pubitemid 28175749)
20. García-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Blair A, Kalaylioglu Z, Rymkiewicz G, Mazepa-Sikora D, Kordek R, Lukaszek S, Sherman ME (2006) Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 95(1):123-129. doi:10.1038/sj.bjc.6603207 (Pubitemid 43980566)
21. Horne HN, Sherman ME, Garcia-Closas M, Pharoah PD, Blows FM, Yang XR, Hewitt SM, Conway CM, Lissowska J, Brinton LA, Prokunina-Olsson L, Dawson SJ, Caldas C, Easton DF, Chanock SJ, Figueroa JD (2014) Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. Breast Cancer Res Treat 143(1):181-187. doi:10.1007/s10549-013-2771-z
22. Mulligan AM, Pinnaduwage D, Bull SB, O'Malley FP, Andrulis IL (2008) Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort. Clin Cancer Res 14(13):4168-4174. doi:10.1158/1078-0432.CCR-07-4543
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Diagnostics SSoN-EWGoC (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235. doi:10.1007/s10549-006-9242-8 (Pubitemid 44631925)
24. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PTK, Groome NP, Speirs V (2008) Nuclear and cytoplasmic expression of ER beta 1, ER beta 2, and ER beta 5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14(16):5228-5235. doi:10.1158/1078-0432.ccr-07-4528
25. Leung YK, Lam HM, Wu SL, Song D, Levin L, Cheng LA, Wu CL, Ho SM (2010) Estrogen receptor beta 2 and beta 5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer 17(3):675-689. doi:10.1677/erc-09-0294
26. Fox EM, Davis RJ, Shupnik MA (2008) ER beta in breast cancer - onlooker, passive player, or active protector? Steroids 73(11):1039-1051. doi:10.1016/j.steroids.2008.04.006
27. Wu X, Subramaniam M, Negron V, Cicek M, Reynolds C, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, Hawse JR (2012) Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody. J Cell Biochem 113(2):711-723. doi:10.1002/jcb.23443
28. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SAW (2004) Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 10(22):7490-7499 (Pubitemid 39557510)
29. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G (2008) Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26(22):3727-3734. doi:10.1200/jco.2007.14.2968
30. Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, Keramopoulos A (2004) The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 57(5):523-528. doi:10.1136/jcp.2003.008599 (Pubitemid 38655949)
31. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustallsson JA, Rochefort H (2004) Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 10(17):5769-5776. doi:10.1158/1078-0432.ccr-04- 0389 (Pubitemid 39180954)